ZYUS Life Sciences Corporation's stock remains stable amid a backdrop of recent financial maneuvering.
This week, ZYUS Life Sciences Corporation (ZYUS.V) has seen no significant price change, maintaining a last close of C$0.50. The company's recent headlines reflect its ongoing efforts to stabilize its financial position and regain investor confidence.
Investor takeaway: With ZYUS Life Sciences trading at the lower end of its 52-week range, investors may want to monitor the company's progress on its financial initiatives and market conditions closely.
Advertisement
ZYUS Life Sciences Corporation
ZYUS.V
ZYUS.V
ZYUS Life Sciences Corporation
WealthAwesomeMarket cap
$39.86M
52W high
$0.74
52W low
$0.40
1W change
+0.00%
Beta
0.46
Analyst Price Targets
Based on analyst covering ZYUS
Wall Street analysts forecast ZYUS stock price to rise 200.0% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$1.50
+200.0% Upside
Current Price
C$0.50
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on ZYUS's historical volatility
30-Day Vol
109.3%
Annualized
90-Day Vol
83.9%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$0.42
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$0.47 | C$0.32 โ C$0.69 |
| 60 trading days | C$0.44 | C$0.26 โ C$0.76 |
| 90 trading days | C$0.42 | C$0.22 โ C$0.80 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Market cap stands at approximately C$39.9 million.
ZYUS Life Sciences has a profit margin of 0.0% and a staggering return on equity of -3516.8%, indicating significant challenges in generating profit.
Bull case
Analysts are optimistic about ZYUS Life Sciences, with an average target price of C$1.50. This suggests thereโs potential for significant gains from the current levels, reflecting a belief in the company's future recovery.
Bear case
However, the company's ongoing financial struggles, including a negative return on equity and a profit margin of 0.0%, raise concerns about its long-term viability. Investors should consider these factors when evaluating their positions.
Price Action Overview
ZYUS Life Sciences Corporation has not experienced any price movement this week, closing at C$0.50. The stock has maintained this price point consistently, reflecting a stable trading environment despite the company's financial challenges.
Recent Company News
Advertisement
There were no major announcements from ZYUS Life Sciences this week. However, the company has been active in the past few months with various financing efforts, including the closure of a fourth tranche of secured loan financing, which raised CAD$50,000. This is part of the company's strategy to stabilize its financial footing and ensure liquidity.
Technical Picture
Currently, ZYUS Life Sciences is trading at the 50-day moving average of C$0.50, indicating a neutral trend. The 200-day moving average stands at C$0.57, suggesting that the stock is underperforming compared to its longer-term trend. The stock's 52-week range is C$0.40 to C$0.74, with the current price at approximately 29% of this range. The beta of 0.46 indicates lower volatility compared to the overall market, which may appeal to risk-averse investors.
Volume Insights
The latest trading volume for ZYUS Life Sciences was 3,022 shares, significantly lower than the 20-day average volume of 13,976 shares, indicating reduced trading activity. This lower volume could reflect investor caution or a lack of interest in the stock at its current price level.
Analyst Outlook
Despite the company's challenges, analysts maintain a bullish outlook with an average target of C$1.50, indicating a potential upside of 200% from its current trading price. This suggests that there is optimism regarding the company's future performance and recovery in the health care sector.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile โโ Reviewed by Certified Financial Professionals
This content has been reviewed by CFAยฎ charterholders and Certified Financial Planners (CFPยฎ) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFAยฎ charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFPยฎ professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
โ ๏ธ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
